Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
暂无分享,去创建一个
H. Handa | A. Klippel | R. Chopra | Lei Wu | Takumi Ito | P. Schafer | H. Ando | T. Daniel | Courtney G. Havens | C. G. Havens | A. Thakurta | M. Waldman | A. Gandhi | Jian Kang | Thomas Conklin | Y. Ning | Yuhong Ning | Thomas O. Daniel
[1] Anita Gandhi,et al. Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients , 2013, PloS one.
[2] E. Petretto,et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. , 2013, Blood.
[3] J. Seavitt,et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression , 2012, Nature Immunology.
[4] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[5] P. L. Bergsagel,et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.
[6] Edward L. Huttlin,et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. , 2011, Molecular cell.
[7] H. Weiner,et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells , 2010, Nature Immunology.
[8] Liming Yang,et al. Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. , 2010, Oncology reports.
[9] M. Mandal,et al. Ikaros and Aiolos Inhibit Pre-B-Cell Proliferation by Directly Suppressing c-Myc Expression , 2010, Molecular and Cellular Biology.
[10] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[11] P. Debré,et al. Differential aiolos expression in human hematopoietic subpopulations. , 2010, Leukemia research.
[12] Q. Cai,et al. Helios Deficiency Has Minimal Impact on T Cell Development and Function1 , 2009, The Journal of Immunology.
[13] U. Frey,et al. The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia , 2009, British journal of haematology.
[14] A. Dalgleish,et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , 2009, Cancer Immunology, Immunotherapy.
[15] R. Foà,et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. , 2008, Blood.
[16] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[17] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[18] O. Laskin,et al. Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis , 2007, Journal of clinical pharmacology.
[19] Chunxia Chen,et al. Ikaros Enforces the Costimulatory Requirement for IL2 Gene Expression and Is Required for Anergy Induction in CD4+ T Lymphocytes1 , 2007, The Journal of Immunology.
[20] F. Macian,et al. Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. , 2007, Blood.
[21] A. Fisher,et al. Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. , 2007, Immunity.
[22] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[23] G. Wolbring,et al. Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.
[24] A. Dalgleish,et al. Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity1 , 2002, The Journal of Immunology.
[25] H. Sather,et al. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Haslett,et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.
[27] K. Georgopoulos,et al. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes , 1999, The EMBO journal.
[28] R. Kingston,et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. , 1999, Immunity.
[29] B. Morgan,et al. Aiolos regulates B cell activation and maturation to effector state. , 1998, Immunity.
[30] A. Sharpe,et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. , 1996, Immunity.